Yousif Capital Management LLC Increases Stock Position in Glaukos Corporation $GKOS

Yousif Capital Management LLC raised its holdings in Glaukos Corporation (NYSE:GKOS) by 4.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,788 shares of the medical instruments supplier’s stock after purchasing an additional 1,011 shares during the period. Yousif Capital Management LLC’s holdings in Glaukos were worth $2,250,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Wellington Management Group LLP lifted its holdings in shares of Glaukos by 6.1% in the first quarter. Wellington Management Group LLP now owns 2,290,790 shares of the medical instruments supplier’s stock valued at $225,460,000 after purchasing an additional 131,251 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Glaukos by 56.5% in the first quarter. Alliancebernstein L.P. now owns 1,277,539 shares of the medical instruments supplier’s stock valued at $125,735,000 after purchasing an additional 461,386 shares in the last quarter. Primecap Management Co. CA lifted its holdings in shares of Glaukos by 0.3% in the first quarter. Primecap Management Co. CA now owns 1,218,475 shares of the medical instruments supplier’s stock valued at $119,922,000 after purchasing an additional 4,150 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of Glaukos by 34.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,084,184 shares of the medical instruments supplier’s stock valued at $106,705,000 after purchasing an additional 277,033 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its holdings in shares of Glaukos by 18.7% in the first quarter. Driehaus Capital Management LLC now owns 973,625 shares of the medical instruments supplier’s stock valued at $95,824,000 after purchasing an additional 153,502 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on GKOS shares. Citigroup reduced their price objective on shares of Glaukos from $140.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, October 7th. Zacks Research downgraded shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. BTIG Research reduced their price objective on shares of Glaukos from $118.00 to $104.00 and set a “buy” rating on the stock in a research note on Monday, October 13th. Wells Fargo & Company upped their price objective on shares of Glaukos from $86.00 to $92.00 and gave the company an “equal weight” rating in a research note on Thursday, July 31st. Finally, Mizuho set a $130.00 price objective on shares of Glaukos in a research note on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $116.92.

Glaukos Stock Performance

Shares of GKOS stock opened at $87.49 on Friday. Glaukos Corporation has a one year low of $77.10 and a one year high of $163.71. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. The company has a 50 day moving average price of $87.74 and a 200 day moving average price of $92.17. The firm has a market capitalization of $5.02 billion, a price-to-earnings ratio of -53.02 and a beta of 0.76.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The firm had revenue of $124.12 million during the quarter, compared to analyst estimates of $115.49 million. During the same quarter in the prior year, the business posted ($0.52) earnings per share. Glaukos’s revenue for the quarter was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.